Veris Ocular Sciences

Veris Ocular Sciences

September 28, 2005 17:15 ET

New Treatment, New Hope for People Suffering from Dry AMD

Attention: Health/Medical Editor, News Editor TORONTO, ONTARIO--(CCNMatthews - Sept. 28, 2005) - With an aging population and with 2.1 million Canadians already suffering from some form of the age-related macular degeneration (AMD), Veris Ocular Sciences wants to share some good news - there is a new and promising treatment called rheopheresis that is proving very effective in treating the dry form of AMD.

AMD is a disease of the eye that occurs in two forms - dry and wet. With dry AMD the deterioration of the light sensitive cells in the eye causes central vision and subtle color loss and distortion that can have a negative effect on such activities as driving and reading. The wet form of AMD is more serious and progressive and can lead to blindness. Studies have indicated that patients with late stage dry AMD have significant chance of developing wet AMD.

Rheopheresis treatment offers real hope to people coping with dry AMD and concerned about protecting their vision. It is a non-invasive procedure that uses a plasma filtering technology to filter out of the blood specific macro-proteins and fatty molecules that in the case of dry AMD act to reduce microcirculation in the eye. By improving blood circulation and the delivery of nutrients to the eye the treatment helps to stabilize the condition, prevent further damage to the retina and may, in some cases, actually improve vision.

Also, by stabilizing dry AMD, rheopheresis aims to reduce the risk that people will develop wet AMD and the severe vision losses that normally result. Medical studies and clinical trails conducted over the last ten years in Europe, the United States and Canada have demonstrated the safety and effectiveness of rheopheresis as a treatment for dry AMD.

For information, please visit

For further information, please contact:
Chris Wright
Optimum Public Relations
(613) 563-2292, ext 232

Contact Information